Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
Delayed Quote. Delayed Nasdaq - 07/23 04:00:00 pm
3.62 USD   -3.98%
07/22European ADRs Modestly Lower Thursday as Unilever Slides
MT
07/21European ADRs Move Sharply Higher in Wednesday Trading
MT
07/20European ADRs Up 0.5% Tuesday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ADAPTIMMUNE THERAPEUTICS PLC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

05/19/2021 | 05:10pm EDT

Item 7.01 Regulation FD Disclosure.

On May 19, 2021, Adaptimmune Therapeutics plc issued a press release announcing that initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), will be reported at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today, May 19, 2021. Data will be presented in an oral presentation by Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center (Abstract #11504) on June 4, 2021.

The press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.


(d)  Exhibits.

Exhibit No.                           Description of Exhibit

   99.1          Press release dated May 19, 2021

    104        Cover Page Interactive Date File (embedded within the Inline XBRL
               document)

© Edgar Online, source Glimpses

All news about ADAPTIMMUNE THERAPEUTICS PLC
07/22European ADRs Modestly Lower Thursday as Unilever Slides
MT
07/21European ADRs Move Sharply Higher in Wednesday Trading
MT
07/20European ADRs Up 0.5% Tuesday
MT
07/07European ADRs Nearly Flat Wednesday as Miners, Techs Gain
MT
07/02European ADRs Move Lower in Friday Trading
MT
06/30European ADRs Move Lower in Wednesday Trading
MT
06/23European ADRs Edge Higher in Wednesday Trading
MT
06/18European ADRs Down More Than 2% Friday as Banks, Drillers Drop
MT
06/16European ADRs Flat in Wednesday Morning Trading
MT
06/15European ADRs Flat in Tuesday Trading
MT
More news
Financials (USD)
Sales 2021 2,61 M - -
Net income 2021 -159 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,63x
Yield 2021 -
Capitalization 563 M 563 M -
Capi. / Sales 2021 215x
Capi. / Sales 2022 31,0x
Nbr of Employees 462
Free-Float 7,23%
Chart ADAPTIMMUNE THERAPEUTICS PLC
Duration : Period :
Adaptimmune Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIMMUNE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 3,62 $
Average target price 9,50 $
Spread / Average Target 162%
EPS Revisions
Managers and Directors
Adrian Rawcliffe Chief Executive Officer & Director
Gavin Wood Chief Financial Officer
David M. Mott Chairman
Elliot Norry Chief Medical Officer
William C. Bertrand Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAPTIMMUNE THERAPEUTICS PLC-32.84%676
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308